Enavate Sciences GP, LLC

10% owner Enavate Sciences buys 1,363,636 CAMP shares at $11.00 ($15.0M), holdings rise to 3,785,802 shares; 6 insiders also bought in past 14 days

Enavate Sciences GP, LLC, a 10% owner, purchased 1,363,636 shares at $11.00 on 2024-10-15, increasing holdings from 2,422,166 to 3,785,802 shares. This $15.0M investment represents a 56.3% increase in the filer's shareholding. The transaction occurred within a 14-day window in which 6 other insiders also executed purchases—a cluster buy pattern that suggests coordinated insider interest. At the $10.86 current price, the stock is -0.6% from its 52-week high of $10.92, having surged +2615.0% over the past 30 and 90 days, indicating recent material price appreciation. The timing of this large accumulation alongside broad insider buying interest merits investor scrutiny of what event or catalyst may have triggered the coordinated activity.

10% owner Enavate Sciences buys 882,353 shares at $17.00 ($15.0M); holdings rise to 3,761,359 shares as 6 other insiders also buy.

Enavate Sciences GP, LLC, a 10% owner, purchased 882,353 shares at $17.00 for $15,000,001.00 on 2024-09-16, increasing post-transaction holdings to 3,761,359 shares from 2,879,006 shares (+30.6% increase). This substantial $15.0M acquisition occurs within a four-day post-IPO window and coincides with a cluster of six other insider purchases within the past 14 days, suggesting coordinated accumulation during early trading. The current price of $17.90 as of 2024-09-18 represents modest upward movement from the transaction price, with limited historical context given the recent listing. The filing involves derivative-conversion mechanics; the full position assessment requires review of Table II derivative securities, which are not yet populated in this database, so the reported 3.76M shares should not be interpreted as the insider's complete equity stake.